• Jump to main navigation
  • Jump to content
U of U Health
  • Billing & Insurance
  • MyChart
Search
  • Find A U of U Health Doctor
  • All U of U Health Services
  • All U of U Health Locations
  • For All U of U Health Patients & Visitors
    • Patient Services
      • Questions About Your Bill?
      • Urgent Care
      • Where to Stay
      • Patients & Family Services
      • Clinical Trials
    • University of Utah Hospital
      • University of Utah Hospital
      • Staying at the Hospital
      • Parking & Valet
      • Looking for Another Location?
    • General Questions
      • 801-581-2668
      • Find an Interpreter
      • About U of U Health
  • Billing & Insurance
  • MyChart
  • Search

Howard Colman, MD, PhD

  • Clinical Information
  • Academic Information
  • Clinical Trials
  • Patient Resources
  • Videos & News
No Rating Available?
In order to provide our patients and visitors with the most accurate and useful information, we only post physician satisfaction data when a physician has received a minimum of 30 returned surveys. For this provider, we have not yet received the minimum.
93 4.6 out of 5 Patient Rating

Languages Spoken: English

Howard Colman, MD, PhD, has multiple clinical interests including the treatment of primary and metastatic brain tumors, and the diagnosis and management of neurologic complications of cancer. His clinical research is focused on the development and testing of new therapies for brain tumors. His laboratory interests include the identification of molecular markers of prognosis and treatment response in brain tumors and the role of tumors stem cells in the development and treatment resistance of brain tumors. He is a Jon M. Huntsman Presidential Professor in the Department of Neurosurgery, a member of the multidisciplinary Brain Tumor Research Team, and is Leader of the Center for Neurologic Cancers at Huntsman Cancer Institute (HCI) at the University of Utah. He is also an HCI investigator and a member of the Experimental Therapeutics program.

Clinical Locations

Huntsman Cancer Institute
Clinic 2E, Neuro

801-585-0262

2000 Circle of Hope
Salt Lake City, UT  84112
Map

Specialties

  • Brain Tumors
  • Spinal Cord Tumors
  • General Neurology
  • Neurosurgery
  • Neuro-Oncology

Board Certification and Academic Information

Academic Departments Neurosurgery - Professor
Internal Medicine - Adjunct Professor
Neurology - Adjunct Professor
Academic Divisions Adult Neurosurgery
Oncology
Board Certification American Board of Psychiatry & Neurology (Neurology)
United Council for Neurologic Subspecialties (Neuro-oncology)
Cancer Center Programs Experimental Therapeutics

Patient Rating

The Patient Rating score is an average of all responses to care provider related questions on our nationally-recognized Press Ganey Patient Satisfaction Survey.

Responses are measured on a scale of 1 to 5 with 5 being the best score.

Learn About Our Survey

Likelihood of recommending care provider

4.7/ 5

Care provider's explanation of condition/problem

4.6/ 5

Care provider's effort to include me in decisions

4.5/ 5

Wait time at clinic

3.8/ 5

Care provider's concern for questions & worries

4.6/ 5

Patient Comments

Patient comments are gathered from our Press Ganey Patient Satisfaction Survery and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.

UofU Patient November 20, 2020
HUNTSMAN CANCER CENTER

5 out of 5 stars

especially appreciated the PA's attentiveness and expertise

UofU Patient November 19, 2020
HUNTSMAN CANCER CENTER

5 out of 5 stars

I think I have the best Doctor's available to anyone. thank you

UofU Patient November 15, 2020
HUNTSMAN CANCER CENTER

4 out of 5 stars

provider suggested several options, but I didn't leave with that information in hand.

UofU Patient October 19, 2020
HUNTSMAN CANCER CENTER

4 out of 5 stars

Good

UofU Patient October 12, 2020
HUNTSMAN CANCER CENTER

5 out of 5 stars

Everything about the visit and personnel was like a well-oiled machine...

UofU Patient October 07, 2020
HUNTSMAN CANCER CENTER

5 out of 5 stars

Everyone was amazing!

UofU Patient August 19, 2020
HUNTSMAN CANCER CENTER

5 out of 5 stars

Highly recommend! Everyone cares about my current, previous, and future health.

UofU Patient July 29, 2020
HUNTSMAN CANCER CENTER

4 out of 5 stars

good

UofU Patient May 24, 2020
HUNTSMAN CANCER CENTER

4 out of 5 stars

good

UofU Patient May 12, 2020
HUNTSMAN CANCER CENTER

5 out of 5 stars

good explanations were given

UofU Patient April 27, 2020
HUNTSMAN CANCER CENTER

4 out of 5 stars

good

UofU Patient April 14, 2020
HUNTSMAN CANCER CENTER

5 out of 5 stars

We were very happy to hear that the course of treatment was also recommended by Dr. Colman and his team. We appreciate the honesty, transparency and explanation of diagnosis that the team offered to us in a way we could understand. Thank you for confirming our treatment plans were exactly what we needed to do.

UofU Patient April 10, 2020
HUNTSMAN CANCER CENTER

5 out of 5 stars

video visit - it was great.

UofU Patient February 17, 2020
HUNTSMAN CANCER CENTER

5 out of 5 stars

Dr./care provider gave updates to my current condition, listened to my questions/concerns, included and explaineddecisions, and I highly recommend to others.

UofU Patient December 14, 2019
HUNTSMAN CANCER CENTER

4 out of 5 stars

good

UofU Patient November 23, 2019
HUNTSMAN CANCER CENTER

5 out of 5 stars

The entire TEAM was knowledgeable, attentive and compassionate.

UofU Patient October 28, 2019
HUNTSMAN CANCER CENTER

4 out of 5 stars

good

UofU Patient October 07, 2019
HUNTSMAN CANCER CENTER

5 out of 5 stars

they weren't very good to answer any Questions I had. Very friendly!

UofU Patient October 07, 2019
HUNTSMAN CANCER CENTER

5 out of 5 stars

the best that has come out of terrible circumstances

UofU Patient September 02, 2019
HUNTSMAN CANCER CENTER

5 out of 5 stars

The staight forward approach was much appreciated.

UofU Patient July 16, 2019
HUNTSMAN CANCER CENTER

4 out of 5 stars

good

UofU Patient June 19, 2019
HUNTSMAN CANCER CENTER

5 out of 5 stars

Great Doctor and PA!

UofU Patient April 08, 2019
HUNTSMAN CANCER CENTER

4 out of 5 stars

good

UofU Patient February 22, 2019
HUNTSMAN CANCER CENTER

4 out of 5 stars

good

UofU Patient February 01, 2019
HUNTSMAN CANCER CENTER

5 out of 5 stars

Even though we have seen Dr. Colman on a regular basis he always takes the time to listen and answer all of our questions completely. His answers are always honest. He doesn't rush through the appointment or assume we understand. We receive best in class service every single time.

UofU Patient January 27, 2019
HUNTSMAN CANCER CENTER

5 out of 5 stars

Dr. Colman is a very straight forward Doctor. When I asked him some tough questions and he provided no nonsense answers.

UofU Patient May 20, 2018

I felt Dr. Colman could have taken more time looking over the MRI and explaining it to me.

UofU Patient May 19, 2018

good

UofU Patient May 06, 2018

I was very impressed by how prompt my questions were answered on MyChart.

UofU Patient March 22, 2018

Doctor Coleman was also very good with my family

UofU Patient February 20, 2018

This was my first time seeing Dr. Colman, I have seen Dr. Cohen in the past. I was very impressed with Dr. Colman's demeanor with me and his frankness in conversation.

UofU Patient February 02, 2018

We always receive world class service. We trust our team and see them as partners in our journey.

UofU Patient January 26, 2018

everything positive

UofU Patient January 18, 2018

very good

UofU Patient November 18, 2017

#1 in my books

UofU Patient August 10, 2017

they pay attention to my comments and observations

UofU Patient April 23, 2017

Dr. Colman used a lot of medical jargon that was hard for me to follow, especially for an early morning appointment (tired)

UofU Patient January 23, 2017

The best!

UofU Patient January 09, 2017

I have the very best team

UofU Patient December 23, 2016

good experience but a bit overwhelming

UofU Patient November 29, 2016

I really felt like I was heard and they were on my team for my treatment.

UofU Patient October 23, 2016

always well taken care ofwith kiley, sean and dr coleman

UofU Patient April 13, 2016

very good

UofU Patient April 10, 2016

no complaints. I have complete confidence in this team

UofU Patient February 11, 2016

I am one of those that typically gives strong critical feedback, especially negative in nature when it is appropriate. I don't have any related to this visit. The Doctor was courteous, on time, and straightforward.

UofU Patient January 11, 2016

I am the second person in my family to meet with this doctor. He took great care to be sure we were comfortable.

UofU Patient January 07, 2016

The Medical Doctor was very helpful and thoughtful. The Technician during the MRI "Rey" was wonderful. He made the MRI experience very pleasant!

UofU Patient November 08, 2015

Your care providers have been great

UofU Patient October 10, 2015

Dr. Coleman is very good at explaining everything

UofU Patient September 23, 2015

I think Dr. Colman is one of the best Nero oncologist in the country. I fly once a year to see him. The trip cost me about $500.00 round trip. I could go to a doctor that is closer but I trust him. He doesn't sugar coat anything and I like that.

UofU Patient September 21, 2015

A great team and they include the patient (and family) in the discussions.

UofU Patient September 09, 2015

Very pleased with our experience and care.

UofU Patient August 24, 2015

great care providers

UofU Patient July 12, 2015

Very happy with Dr. Colman.

UofU Patient July 05, 2015

So far life is good!

UofU Patient July 02, 2015

Sean and Dr. Coleman are both professional and friendly, spend all the time we need and we like them and the care they give.

UofU Patient June 12, 2015

i love love love Kylee, Shawn and Dr. Colman. they make a great team and ALWAYS go the extra mile for anything i need. They are all SUPER compassionate and caring. im glad i FINALLY found a great healthcare team for myself.

UofU Patient May 19, 2015

good

UofU Patient May 11, 2015

The opportunity to work with such an amazing team of professionals almost makes it worth it to have cancer.

UofU Patient April 13, 2015

Dr. Colman is very friendly and always answers my questions and concerns. I feel very blessed to have him as my Dr.

UofU Patient February 16, 2015

My team is great! I am so happy I finally got referred here.

UofU Patient January 28, 2015

Very good Experience

UofU Patient January 12, 2015

Dr. Colman has always fully answered any concerns or questions we might have. We have full trust in his care.

UofU Patient January 10, 2015

Dr. Colman and his staff are awesome. I apologize but I don't know the doctor's name who saw me before Dr. Colman but he was great. He answered my questions and I could tell he was interested in how I was doing and what had gone on since the last time I was there. Dr. Colman was fantastic. I was very glad to hear that he is also over at the VA hospital. He showed me my tumor on the scan and answered all my questions. I trust him with my care.

UofU Patient January 10, 2015

We had a very good experience with Dr. Colman, Sean PA, and nurse Kylee. All 3 were professional and caring. I am so happy I finally found a great team to take care of me. Healthcare these days seems lousy at best, but this team is PHENOMINAL!!!!!!! CANT SAY ENOUGH GOOD ABOUT THEM. THANK YOU THANK YOU THANK YOU!!!!!!!

UofU Patient January 03, 2015

don't get me wrong my medical team is great and wouldn't trade them and I know they're busy but I'm busy too !!!!!

UofU Patient November 01, 2014

Not impressed. When you have cancer their should always be some hope

UofU Patient October 19, 2014

Dr and Assistant are exceptional. We feel very comfortable with them and are able to express our concerns and ask questions.

UofU Patient October 04, 2014

We feel very confidante with Dr Colman

UofU Patient October 03, 2014

Dr. Colman is a genius. He knows absolutely everything there is to know about brain tumors. He was great at educating us about the tumor and the medicine that would help it. I was slightly disappointed by our method of communication. He seemed to feel rushed and wanted to leave as soon as possible. He answered all of our questions, but a patient with a brain tumor needs time to process information.

UofU Patient April 07, 2014

I have been to the clinic for 20 years but had a new doctor at this visit. Dr. Colman was very thorough, informative and patient.

UofU Patient April 06, 2014

Dr Colman is great, his son played lacrosse with my son a few years ago, so he is willing to chat with me personally for a few minutes as well as being very professional in his medical care for me.

UofU Patient March 30, 2014

I was very impressed with the quality of care at Huntsman. We have been to UCLA medical several times and we just moved to Utah and this was a vast improvement over the care we received at UCLA.

UofU Patient March 15, 2014

just like the nursing staff, the PA/MD seemed to be in a hurry. However they seemed to be doing their best to answer all of my questions and not rush the appt

UofU Patient February 03, 2014

I was very impressed that I transferred my care to Hunstman from IMC.

UofU Patient October 30, 2013

The nurse, PA, and doctor were all fantastic and thorough and provided all the information I needed in a way that was easy to understand.

UofU Patient July 06, 2013

love dr Colman. and his staff

UofU Patient May 31, 2013

Very Positive Experience.

UofU Patient May 27, 2013

I have the highest confidence in Dr Colman. He is an excellent physician.

UofU Patient April 22, 2013

Dr Colman is excellent. I respect him and have a significant amount of confidence in his professional ability.

UofU Patient March 28, 2013

I have a lot of confidence in my medical care team.

UofU Patient February 18, 2013

Over the top. I left feeling hopeful and extremely confident with dr Coleman and the entire team

UofU Patient January 22, 2013

I was very happy with the care I was given. I was especially surprised with the degree of time the doctor and pa gave me. Their concern for me was genuine and they made me feel relaxed and better able to understand what they were saying.

UofU Patient November 19, 2012

All clinic staff (doctor, pa, and np) listened carefully to my questions, gave thorough answers and explanations, and made sure I understood next steps.

UofU Patient November 19, 2012

Very clearly outlined the next few steps in my treatment

UofU Patient November 05, 2012

I have recommended to many of my co-workers and family out of state about how awesome our experience was.

UofU Patient August 20, 2012

Dr. Colman is awesome that is all that needs to be said.

UofU Patient July 03, 2012

Between all the staff I was provided with almost 1.5 hours of care during my visit. This was outstanding. Dr Colman was very detail oriented and never seemed rushed - I really appreciated this. The PA seemed very knowledgeable, but very rushed.

UofU Patient June 13, 2012

Dr. Howard Colman, has been very understanding, and communicates clearly, in a manner we can fully understand.

UofU Patient April 27, 2012

Dr. Colman is always well informed on Sherry's latest MRI's and treatments. He gives us substantial input.

UofU Patient March 14, 2012

Include me in the process of making a diagnosis and prescribing the right medication. They are not just doctors that tell you what to do because they said so. They are very involved in what's going on in the patient's mind.

UofU Patient February 22, 2012

They addressed every concern.

UofU Patient January 11, 2012

I am very grateful for the care that I have recieved from Dr. Howard Colman. I have the upmost confidence in them and the way they have treated my condition.

Howard Colman, MD, PhD, has multiple clinical interests including the treatment of primary and metastatic brain tumors, and the diagnosis and management of neurologic complications of cancer. His clinical research is focused on the development and testing of new therapies for brain tumors. His laboratory interests include the identification of molecular markers of prognosis and treatment response in brain tumors and the role of tumors stem cells in the development and treatment resistance of brain tumors. He is a Jon M. Huntsman Presidential Professor in the Department of Neurosurgery, a member of the multidisciplinary Brain Tumor Research Team, and is Leader of the Center for Neurologic Cancers at Huntsman Cancer Institute (HCI) at the University of Utah. He is also an HCI investigator and a member of the Experimental Therapeutics program.

Academic Locations

Huntsman Cancer Institute

801-587-4024

2000 Circle of Hope
Salt Lake City, UT  84112

Board Certification and Academic Information

Academic Departments Neurosurgery - Professor
Internal Medicine - Adjunct Professor
Neurology - Adjunct Professor
Academic Divisions Adult Neurosurgery
Oncology
Board Certification American Board of Psychiatry & Neurology (Neurology)
United Council for Neurologic Subspecialties (Neuro-oncology)
Cancer Center Programs Experimental Therapeutics

Research Interests

  • Brain Tumors
  • Clinical Trials
  • Role of Tumors Stem Cells in the Development and Treatment Resistance of Brain Tumors
  • Development and Testing of New Therapies for Brain Tumors
  • Identification of Molecular Markers of Prognosis and Treatment Response in Brain Tumors

Education History

Fellowship University of Texas M.D. Anderson Cancer Center
Neuro-Oncology
Fellow
Chief Resident Washington University School of Medicine
Neurology
Chief Resident
Residency Barnes-Jewish Hospital, Washington University School of Medicine
Neurology
Resident
Internship Barnes-Jewish Hospital, Washington University School of Medicine
Medicine
Intern
Doctoral Training Washington University School of Medicine
Neuroscience
Ph.D.
Professional Medical Washington University School of Medicine
Medicine
M.D.
Undergraduate Brown University
Neural Sciences
Sc.B.

Selected Publications - Journal Articles

Journal Article

  1. Nayak L, Molinaro AM, Peters K, Clarke JL, Jordan JT, de Groot J, Nghiemphu L, Kaley T, Colman H, McCluskey C, Gaffey S, Smith TR, Cote DJ, Severgnini M, Yearley JH, Zhao Q, Blumenschein WM, Duda DG, Muzikansky A, Jain RK, Wen PY, Reardon DA (2020). Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma. (Epub ahead of print) Clin Cancer Res.
  2. Ellingson BM, Brown MS, Boxerman JL, Gerstner ER, Kaufmann TJ, Cole PE, Bacha JA, Leung D, Barone A, Colman H, van den Bent MJ, Wen PY, Yung WKA, Cloughesy TF, Goldin JG (2020). Radiographic Read Paradigms and the Roles of the Central Imaging Laboratory in Neuro-Oncology Clinical Trials. (Epub ahead of print) Neuro-Oncol.
  3. Puduvalli VK, Wu J, Yuan Y, Armstrong TS, Vera E, Wu J, Xu J, Giglio P, Colman H, Walbert T, Raizer J, Groves MD, Tran D, Iwamoto F, Avgeropoulos N, Paleologos N, Fink K, Peereboom D, Chamberlain M, Merrell R, Penas Prado M, Yung WKA, Gilbert MR (2021). A Bayesian adaptive randomized phase II multicenter trial of bevacizumab with or without vorinostat in adults with recurrent glioblastoma. Neuro-Oncol, 22(10), 1505-1515.
  4. Werner CK, Nna UJ, Sun H, Wilder-Romans K, Dresser J, Kothari AU, Zhou W, Yao Y, Rao A, Stallard S, Koschmann C, Bor T, Debinski W, Hegedus AM, Morgan MA, Venneti S, Baskin-Bey E, Spratt DE, Colman H, Sarkaria JN, Chinnaiyan AM, Eisner JR, Speers C, Lawrence TS, Strowd RE, Wahl DR (2020). Expression of the Androgen Receptor Governs Radiation Resistance in a Subset of Glioblastomas Vulnerable to Antiandrogen Therapy. Mol Cancer Ther, 19(10), 2163-2174.
  5. Holowatyj AN, Viskochil R, Ose D, Tingey B, Haaland B, Wilson D, Larson M, Feltz S, Lewis MA, Colman H, Ulrich CM (2020). Diabetes, Body Fatness, and Insulin Prescription Among Adolescents and Young Adults with Cancer. (Epub ahead of print) J Adolesc Young Adult Oncol.
  6. Cohen AL, Anker CJ, Johnson B, Burt LM, Shrieve DC, Salzman K, Jensen R, Boucher K, Colman H (2020). Repeat radiation with bevacizumab and minocycline in bevacizumab-refractory high grade gliomas: a prospective phase 1 trial. J Neurooncol, 148(3), 577-585.
  7. Brat DJ, Aldape K, Colman H, Figrarella-Branger D, Fuller GN, Giannini C, Holland EC, Jenkins RB, Kleinschmidt-DeMasters B, Komori T, Kros JM, Louis DN, McLean C, Perry A, Reifenberger G, Sarkar C, Stupp R, van den Bent MJ, von Deimling A, Weller M (2020). cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas. Acta Neuropathol (Berl), 139(3), 603-608.
  8. Smith-Cohn M, Davidson C, Colman H, Cohen AL (2019). Challenges of targeting BRAF V600E mutations in adult primary brain tumor patients: a report of two cases. CNS Oncol, 8(4), CNS48.
  9. Lim-Fat MJ, Bi WL, Lo J, Lee EQ, Ahluwalia MS, Batchelor TT, Chang SM, Chiocca EA, Chukwueke U, Cloughesy TF, Colman H, Deangelis LM, Galanis E, Gilbert MR, De Groot JF, Lassman AB, Liau LM, Mason W, McFaline-Figueroa JR, Mehta MP, Mellinghoff IK, Nabors LB, Nayak L, Reardon DA, Wen PY (2020). Letter: When Less is More: Dexamethasone Dosing for Brain Tumors. Neurosurgery, 85(3), E607-E608.
  10. Wen PY, Touat M, Alexander BM, Mellinghoff IK, Ramkissoon S, McCluskey CS, Pelton K, Haidar S, Basu SS, Gaffey SC, Brown LE, Martinez-Ledesma JE, Wu S, Kim J, Wei W, Park MA, Huse JT, Kuhn JG, Rinne ML, Colman H, Agar NYR, Omuro AM, DeAngelis LM, Gilbert MR, de Groot JF, Cloughesy TF, Chi AS, Roberts TM, Zhao JJ, Lee EQ, Nayak L, Heath JR, Horky LL, Batchelor TT, Beroukhim R, Chang SM, Ligon AH, Dunn IF, Koul D, Young GS, Prados MD, Reardon DA, Yung WKA, Ligon KL (2019). Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial. J Clin Oncol, 37(9), 741-750.
  11. Cloughesy TF, Mochizuki AY, Orpilla JR, Hugo W, Lee AH, Davidson TB, Wang AC, Ellingson BM, Rytlewski JA, Sanders CM, Kawaguchi ES, Du L, Li G, Yong WH, Gaffey SC, Cohen AL, Mellinghoff IK, Lee EQ, Reardon DA, OBrien BJ, Butowski NA, Nghiemphu PL, Clarke JL, Arrillaga-Romany IC, Colman H, Kaley TJ, de Groot JF, Liau LM, Wen PY, Prins RM (2019). Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat Med, 25(3), 477-486.
  12. Hummel S, Kohlmann W, Kollmeyer TM, Jenkins R, Sonnen J, Palmer CA, Colman H, Abbott D, Cannon-Albright L, Cohen AL (2019). The contribution of the rs55705857 G allele to familial cancer risk as estimated in the Utah population database. BMC Cancer, 19(1), 190.
  13. Wang Y, Xu X, Maglic D, Dill MT, Mojumdar K, Ng PK, Jeong KJ, Tsang YH, Moreno D, Bhavana VH, Peng X, Ge Z, Chen H, Li J, Chen Z, Zhang H, Han L, Du D, Creighton CJ, Mills GB, Cancer Genome Atlas Research Network, Camargo F, Liang H (2018). Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer. Cell Rep, 25(5), 1304-1317.e5.
  14. Ippen FM, Colman H, van den Bent MJ, Brastianos PK (2018). Precision Medicine for Primary Central Nervous System Tumors: Are We There Yet? Am Soc Clin Oncol Educ Book, 38(38), 158-167.
  15. Philip B, Yu DX, Silvis MR, Shin CH, Robinson JP, Robinson GL, Welker AE, Angel SN, Tripp SR, Sonnen JA, VanBrocklin MW, Gibbons RJ, Looper RE, Colman H, Holmen SL (2018). Mutant IDH1 Promotes Glioma Formation In Vivo. Cell Rep, 23(5), 1553-1564.
  16. Frandsen J, Orton A, Jensen R, Colman H, Cohen AL, Tward J, Shrieve DC, Suneja G (2018). Patterns of care and outcomes in gliosarcoma: an analysis of the National Cancer Database. J Neurosurg, 128(4), 1133-1138.
  17. Colman H (2017). Toward more informative biomarker-based clinical trials in glioblastoma. Neuro-Oncol, 19(7), 880-881.
  18. Ramaswamy V, Hielscher T, Mack SC, Lassaletta A, Lin T, Pajtler KW, Jones DT, Luu B, Cavalli FM, Aldape K, Remke M, Mynarek M, Rutkowski S, Gururangan S, McLendon RE, Lipp ES, Dunham C, Hukin J, Eisenstat DD, Fulton D, van Landeghem FK, Santi M, van Veelen MC, Van Meir EG, Osuka S, Fan X, Muraszko KM, Tirapelli DP, Oba-Shinjo SM, Marie SK, Carlotti CG, Lee JY, Nageswara Rao AA, Giannini C, Faria CC, Nunes S, Mora J, Hamilton RL, Hauser P, Jabado N, Petrecca K, Jung S, Massimi L, Zollo M, Cinalli G, Bognr L, Klekner A, Hortobgyi T, Leary S, Ermoian RP, Olson JM, Leonard JR, Gardner C, Grajkowska WA, Chambless LB, Cain J, Eberhart CG, Ahsan S, Massimino M, Giangaspero F, Buttarelli FR, Packer RJ, Emery L, Yong WH, Soto H, Liau LM, Everson R, Grossbach A, Shalaby T, Grotzer M, Karajannis MA, Zagzag D, Wheeler H, von Hoff K, Alonso MM, Tuon T, Schller U, Zitterbart K, Sterba J, Chan JA, Guzman M, Elbabaa SK, Colman H, Dhall G, Fisher PG, Fouladi M, Gajjar A, Goldman S, Hwang E, Kool M, Ladha H, Vera-Bolanos E, Wani K, Lieberman F, Mikkelsen T, Omuro AM, Pollack IF, Prados M, Robins HI, Soffietti R, Wu J, Metellus P, Tabori U, Bartels U, Bouffet E, Hawkins CE, Rutka JT, Dirks P, Pfister SM, Merchant TE, Gilbert MR, Armstrong TS, Korshunov A, Ellison DW, Taylor MD (2016). Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis [Epub ahead of print]. J Clin Oncol, 34(21), 2468-2477.
  19. Butowski N, Colman H, De Groot JF, Omuro AM, Nayak L, Wen PY, Cloughesy TF, Marimuthu A, Haidar S, Perry A, Huse J, Phillips J, West BL, Nolop KB, Hsu HH, Ligon KL, Molinaro AM, Prados M (2016). Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study. Neuro Oncol, 18(4), 557-64.
  20. Karsy M, Guan J, Jensen R, Huang LE, Colman H (2016). The Impact of Hypoxia and Mesenchymal Transition on Glioblastoma Pathogenesis and Cancer Stem Cells Regulation. World Neurosurg, 88, 222-236.
  21. Ceccarelli M, et al TCGA Research Network, Colman H (2016). Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma. Cell, 146(3), 550-563.
  22. Sathyan P, Zinn PO, Marisetty AL, Liu B, Kamal MM, Singh SK, Bady P, Lu L, Wani KM, Veo BL, Gumin J, Kassem DH, Robinson F, Weng C, Baladandayuthapani V, Suki D, Colman H, Bhat KP, Sulman EP, Aldape K, Colen RR, Verhaak RG, Lu Z, Fuller GN, Huang S, Lang FF, Sawaya R, Hegi M, Majumder S (2015). Mir-21-Sox2 Axis Delineates Glioblastoma Subtypes with Prognostic Impact. J Neurosci, 35(45), 15097-112.
  23. Yuan S, Lu Y, Yang J, Chen G, Kim S, Feng L, Ogasawara M, Hammoudi N, Lu W, Zhang H, Liu J, Colman H, Lee JS, Li XN, Xu RH, Huang P, Wang F (2015). Metabolic activation of mitochondria in glioma stem cells promotes cancer development through a reactive oxygen species-mediated mechanism. Stem Cell Res Ther, 6(1), 198.
  24. Balasubramaniyan V, Vaillant B, Wang S, Gumin J, Butalid ME, Sai K, Mukheef F, Kim SH, Boddeke HW, Lang F, Aldape K, Sulman EP, Bhat KP, Colman H (2015). Aberrant mesenchymal differentiation of glioma stem-like cells: implications for therapeutic targeting. Oncotarget, 6(31), 31007-17.
  25. Hossain A, Gumin J, Gao F, Figueroa J, Shinojima N, Takezaki T, Priebe W, Villarreal D, Kang SG, Joyce C, Sulman E, Wang Q, Marini FC, Andreeff M, Colman H, Lang FF (2015). Mesenchymal Stem Cells Isolated From Human Gliomas Increase Proliferation and Maintain Stemness of Glioma Stem Cells Through the IL-6/gp130/STAT3 Pathway. Stem Cells, 33(8), 2400-15.
  26. Cohen A, Sato M, Aldape K, Mason CC, Alfaro-Munoz K, Heathcock L, South ST, Abegglen LM, Schiffman JD, Colman H (2015). DNA copy number analysis of Grade II-III and Grade IV gliomas reveals differences in molecular ontogeny including chromothripsis associated with IDH mutation status. Acta Neuropathol Commun, 3, 34.
  27. The Cancer Genome Atlas Network (2015). Comprehensive and Integrative Genomic Characterization of Diffuse Lower Grade Gliomas DOI: 10.1056/NEJMoa1402121 *Includes Colman, H. N Engl J Med, 372(26), 2481-2498.
  28. Choi H, Gillespie DL, Berg S, Rice C, Couldwell S, Gu J, Colman H, Jensen RL, Huang LE (2015). Intermittent induction of HIF-1α produces lasting effects on malignant progression independent of its continued expression. PLoS ONE, 10(4), e0125125.
  29. Vera-Bolanos E, Aldape K, Yuan Y, Wu J, Wani K, Necesito-Reyes MJ, Colman H, Dhall G, Lieberman FS, Metellus P, Mikkelsen T, Omuro A, Partap S, Prados M, Robins HI, Soffietti R, Wu J, Gilbert MR, Armstrong TS, CERN Foundation (2014). Clinical course and progression-free survival of adult intracranial and spinal ependymoma patients. Neuro-Oncol, 17(3), 440-7.
  30. Karsy M, Neil JA, Guan J, Mahan MA, Colman H, Jensen RL (2015). A practical review of prognostic correlations of molecular biomarkers in glioblastoma. Neurosurg Focus, 38(3), E4.
  31. Chen R, Ravindra VM, Cohen AL, Jensen RL, Salzman KL, Prescot AP, Colman H (2015). Molecular features assisting in diagnosis, surgery, and treatment decision making in low-grade gliomas. Neurosurg Focus, 38(3), E2.
  32. Penas-Prado M, Hess KR, Fisch MJ, Lagrone LW, Groves MD, Levin VA, De Groot JF, Puduvalli VK, Colman H, Volas-Redd G, Giglio P, Conrad CA, Salacz ME, Floyd JD, Loghin ME, Hsu SH, Gonzalez J, Chang EL, Woo SY, Mahajan A, Aldape KD, Yung WK, Gilbert MR, MD Anderson Community Clinical Oncology Program, Brain Tumor Trials Collaborative (2015). Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma. Neuro Oncol, 17(2), 266-73.
  33. Cohen AL, Colman H (2015). Glioma biology and molecular markers. Cancer Treat Res, 163, 15-30.
  34. Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S, Won M, Jeraj R, Brown PD, Jaeckle KA, Schiff D, Stieber VW, Brachman DG, Werner-Wasik M, Tremont-Lukats IW, Sulman EP, Aldape KD, Curran WJ Jr, Mehta MP (2014). A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med, 370(8), 699-708.
  35. Saito N, Fu J, Zheng S, Yao J, Wang S, Liu DD, Yuan Y, Sulman EP, Lang FF, Colman H, Verhaak RG, Yung WK, Koul D (2014). A high Notch pathway activation predicts response to gamma secretase inhibitors in proneural subtype of glioma tumor-initiating cells. Stem Cells, 32(1), 301-12.
  36. Bhat KPL, Balasubramaniyan V, Vaillant B, Ezhilarasan R, Hummelink K, Hollingsworth F, Wani K, Heathcock L, James JD, Goodman LD, Conroy S, Long L, Lelic N, Wang S, Gumin J, Raj D, Kodama Y, Raghunathan A, Olar A, Joshi K, Pelloski CE, Heimberger A, Kim SH, Cahill DP, Rao G, Den Dunnen WFA, Boddeke HWGM, Phillips HS, Nakano I, Lang FF, Colman H, Sulman EP, Aldape K (2013). Mesenchymal differentiation mediated by NF-κB promotes radiation resistance in glioblastoma. Cancer Cell, 24(3), 331-46.

Review

  1. Chen R, Cohen AL, Colman H (2016). Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future. [Review]. Curr Treat Options Oncol, 17(8), 42.
  2. Karsy M, Guan J, Cohen A, Colman H, Jensen RL (2016). Medical Management of Meningiomas: Current Status, Failed Treatments, and Promising Horizons. [Review]. Neurosurg Clin N Am, 27(2), 249-60.
  3. Prados MD, Byron SA, Tran NL, Phillips JJ, Molinaro AM, Ligon KL, Wen PY, Kuhn JG, Mellinghoff IK, de Groot JF, Colman H, Cloughesy TF, Chang SM, Ryken TC, Tembe WD, Kiefer JA, Berens ME, Craig DW, Carpten JD, Trent JM (2015). Toward precision medicine in glioblastoma: the promise and the challenges. [Review]. Neuro Oncol, 17(8), 1051-1063.

Case Report

  1. Sivakumar W, Oh N, Cutler A, Colman H, Couldwell WT (2015). Cranial and spinal leptomeningeal dissemination in esthesioneuroblastoma: Two reports of distant central nervous system metastasis and rationale for treatment. Surg Neurol Int, 6(Suppl 25), S628-32.

Editorial

  1. Colman H (2019). A platform for efficient early evaluation of biomarker-associated therapies in newly diagnosed IDH wild-type, MGMT unmethylated glioblastoma. 21(1), 6-7.

Patent

  1. University of Texas M.D. Anderson Cancer Center, Colman H, Zhang L, Aldape K (2009). Multigene Assay to Predict Outcome in an Individual with Glioblastoma. U.S. Patent No. PCT/U808/55472. Washington, D.C.:U.S. Patent and Trademark Office.

Global Impact

Service

10/01/2015 Member GBM International Adaptive Trial Protocol Writing Committee. China

NN106

Description: Not yet recruiting Keywords: brain tumor Principal Investigator: Howard Colman

News Articles

University of Utah Names Six Additional Recipients of the Jon M. Huntsman Presidential Chairs

Huntsman Cancer Institute News

Huntsman Translational Scholars: Howard Colman, MD, PhD

Bench to Bedside

The Scope & Other Podcasts

  • Diagnosis and Treatment of Low Grade Glioma in the Molecular Era
  • RAMBO Clinical Trial
  • Brain, Spine, and Skull Base Cancer Program at Huntsman Cancer Institute
  • Howard Colman, MD, PhD

Videos

RAMBO Clinical Trial

Howard Colman, MD, PhD

Diagnosis and Treatment of Low Grade Glioma in the Molecular Era

Brain, Spine, and Skull Base Cancer Program at Huntsman Cancer Institute

Site Links

  • About Us
  • Academics & Research
  • Billing
  • Jobs
  • Giving
  • Maps & Directions
  • Newsroom
  • The Imagine Perfect Care Program

Helpful Links

  • Referring Providers
  • Find an Interpreter
  • Patient Rights & Responsibilities
  • Disclaimer
  • Privacy Statement
  • DNV GL Public Information Policy Statement
  • Non-Discrimination Policy
  • Webmaster

Contact Us

University of Utah Health

50 North Medical Drive
Salt Lake City, UT 84132

801-581-2121

  • Facebook
  • Twitter
  • Youtube

University of Utah

All clinical services and programs are part of University of Utah Health Hospitals and Clinics.

Copyright © 2021 University of Utah Health